Frazier Life Sciences Management’s Aclaris Therapeutics ACRS Stock Holding History

Frazier Life Sciences Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.5M	Buy	+4,925,374	New	+$16.6M	0.48%	28
2024 Q4	–	Sell	-264,377	Closed	-$304K	–	51
2024 Q3	$304K	Hold	264,377	–	–	0.01%	52
2024 Q2	$291K	Hold	264,377	–	–	0.01%	49
2024 Q1	$328K	Hold	264,377	–	–	0.01%	50
2023 Q4	$278K	Hold	264,377	–	–	0.01%	49
2023 Q3	$1.81M	Hold	264,377	–	–	0.12%	48
2023 Q2	$2.74M	Hold	264,377	–	–	0.16%	46
2023 Q1	$2.14M	Sell	264,377 -25,812	-9%	-$328K	0.15%	47
2022 Q4	$4.57M	Sell	290,189 -118,140	-29%	-$1.9M	0.28%	40
2022 Q3	$6.43M	Hold	408,329	–	–	0.49%	35
2022 Q2	$5.7M	Hold	408,329	–	–	0.54%	31
2022 Q1	$7.04M	Buy	+408,329	New	+$5.57M	0.6%	33

Other funds holding ACRS

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return